These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36575505)

  • 1. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
    Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: Exploratory dual-energy computed tomography findings from MIRROR RCT.
    Dalbeth N; Botson J; Saag K; Kumar A; Padnick-Silver L; LaMoreaux B; Becce F
    Joint Bone Spine; 2024 Jul; 91(4):105715. PubMed ID: 38447697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout.
    Broadwell A; Albert JA; Padnick-Silver L; LaMoreaux B
    Rheumatol Ther; 2022 Dec; 9(6):1549-1558. PubMed ID: 36136270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series.
    Albert J; Broadwell A; Padnick-Silver L; Marder B; LaMoreaux B
    Medicine (Baltimore); 2024 Mar; 103(10):e37424. PubMed ID: 38457582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR).
    Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; LaMoreaux B; Weinblatt ME; Peterson J
    J Rheumatol; 2021 May; 48(5):767-774. PubMed ID: 32934137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
    Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
    Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
    Botson JK; Saag K; Peterson J; Parikh N; Ong S; La D; LoCicero K; Obermeyer K; Xin Y; Chamberlain J; LaMoreaux B; Verma S; Sainati S; Grewal S; Majjhoo A; Tesser JRP; Weinblatt ME
    Arthritis Rheumatol; 2023 Feb; 75(2):293-304. PubMed ID: 36099211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
    Schlesinger N; Lipsky PE
    Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy.
    Dalbeth N; Becce F; Botson JK; Zhao L; Kumar A
    Rheumatology (Oxford); 2022 Nov; 61(12):4898-4904. PubMed ID: 35293984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study.
    Albert JA; Hosey T; LaMoreaux B
    Rheumatol Ther; 2020 Sep; 7(3):639-648. PubMed ID: 32720081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
    Bessen SY; Bessen MY; Yung CM
    Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
    Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
    Keenan RT; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2022 May; 40(5):1006-1010. PubMed ID: 35238750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
    Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation.
    Holladay EE; Mudano AS; Xie F; Zhang J; Mikuls TR; LaMoreaux B; Padnick-Silver L; Curtis JR
    Arthritis Res Ther; 2024 Apr; 26(1):86. PubMed ID: 38609967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.